How to leverage an endogenous immune defense mechanism: The example of granulocyte colony-stimulating factor

Critical Care Medicine

Volumn 31, Issue 1 SUPPL., 2003, Pages

  Hartung, Thomas ^a   Von Aulock, Sonja ^b   Schneider, Christian ^b   Faist, Eugen ^b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Clinical trials; Endogenous production; Granulocyte colony stimulating factor; Infection; Inflammation; Perioperative immunomodulation; Pleiotropy; Redundancy; Safety; Sepsis

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE PHASE RESPONSE; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIOPERATIVE PERIOD; PLEIOTROPY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; TH1 CELL; TH2 CELL;

EID: 0037251467     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200301001-00010     Document Type: Review

References (66)

1. Quinton LJ, Nelson S, Boe DM, et al: The granulocyte colony-stimulating factor response after intrapulmonary and systemic bacterial challenges. J Infect Dis 2002; 185: 1476-1482
2. Lieschke GJ, Grail D, Hodgson G, et al: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737-1746
3. Liu F, Wu HY, Wesselschmidt R, et al: Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996; 5:491-501
4. Mandel L, Talafantova M, Trebichavsky I, et al: Selective decontamination, induced colonization resistance and connected immunological changes in piglets. Folia Microbiol 1985; 30:312-318
5. MacVittie TJ, Walker RI: Canine granulopoiesis: Alterations induced by suppression of gram-negative flora. Exp Hematol 1978; 6:639-647
6. Shimazaki C, Uchiyama H, Fujita N, et al: Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. Exp Hematol 1995; 23:1497-1502
7. Houston AC, Stevens LA, Cour V: Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. Br J Clin Pharmacol 1999; 47:279-284
8. Layton JE, Hockman H, Sheridan WP, et al: Evidence for a novel in vivo control mechanism of granulopoiesis: Mature cell-related control of a regulatory growth factor. Blood 1989; 74:1303-1307
9. Kuwabara T, Kobayashi S, Sugiyama Y: Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 1996; 28:625-658
10. Fukuda M, Oka M, Ishida Y, et al: Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients. Antimicrob Agents Chemother 2001; 45: 1947-1951
11. Tanaka H, Ishikawa K, Nishino M, et al: Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma 1996;40:718-725; Discussion 725-726
12. Gross-Weege W, Dumon K, Dahmen A, et al: Granulocyte colony-stimulating factor (G-CSF) serum levels in surgical intensive care patients. Infection 1997; 25:213-216
13. Philpott NJ, Prue RL, Marsh JC, et al: G-CSF-mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: Role of G-CSF as survival factor. Br J Haematol 1997; 97:146-152
14. Ina K, Kusugami K, Hosokawa T, et al: Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in inflammatory bowel disease. J Gastroenterol Hepatol 1999; 14:46-53
15. Leavey PJ, Sellins KS, Thurman G, et al: In vivo treatment with granulocyte colony-stimulating factor results in divergent effects on neutrophil functions measured in vitro. Blood 1998; 92:4366-4374
16. Ertel W, Keel M, Buergi U, et al: Granulocyte colony-stimulating factor inhibits neutrophil apoptosis at the local site after severe head and thoracic injury. J Trauma 1999;46: 784-792; Discussion 792-793
17. Gabrilove JL, Jakubowski A, Fain K, et al: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82;1454-1461
18. Hartung T, Doecke WD, Bundschuh D, et al: Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Ther 1999; 66:415-424
19. von Aulock S, Boneberg EM, Hartung T: Intermittent G-CSF (filgrastim) treatment cannot induce lymphocytosis in volunteers. Clin Pharmacol Ther 2000; 68:104
20. Weinthal JA, Nemunaitis JJ, Aston S, et al: Analysis of apheresis content of progenitor cell collections from normal donors to whom granulocyte-colony-stimulating factor is administered. Transfusion 1996; 36:943-947
21. Boneberg EM, Hartung T: Molecular aspects of anti-inflammatory action of G-CSF. Inflamm Res 2002; 51:119-128
22. Hartung T: Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 1998; 5:221-225
23. Boneberg EM, Hareng L, Gantner F, et al: Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 2000; 95: 270-276
24. Boneberg EM, Hartung T: Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proTNF-alpha formation. Eur J Immunol 2002; 32: 1717-1725
25. Hartung T, Döcke WD, Gantner F, et al: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85:2482-2489
26. Chen YM, Whang-Peng J, Chern CH, et al: The prognostic value of serum cytokine levels in patients with acute infections. Zhonghua Yi Xue Za Zhi (Taipei) 1995; 56:75-79
27. Fischer JE, Benn A, Harbarth S, et al: Diagnostic accuracy of G-CSF, IL-8, and IL-1ra in critically ill children with suspected infection. Intensive Care Med 2002; 28: 1324-1331
28. Buscher U, Chen FC, Pitzen A, et al: Il-1 beta, Il-6, Il-8 and G-CSF in the diagnosis of early-onset neonatal infections. J Perinat Med 2000; 28:383-388
29. Slotman GJ: Prospectively validated prediction of physiologic variables and organ failure in septic patients: The Systemic Mediator Associated Response Test (SMART). Crit Care Med 2002; 30:1035-1045
30. Hareng L, Hartung T: Induction and regulation of endogenous granulocyte colony-stimulating factor formation. Biol Chem 2002; 383 (In Press)
31. Pauksen K, Elfman L, Ulfgren AK, et al: Serum levels of granulocyte-colony stimulating factor (G-CSF) in bacterial and viral infections, and in atypical pneumonia. Br J Haematol 1994; 88:256-260
32. Taveira da Silva AM, Kaulbach HC, Chuidian FS, et al: Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993; 328: 1457-1460
33. Weiss M, Fischer G, Barth E, et al: Dissociation of LPS-induced monocytic ex vivo production of granulocyte colony-stimulating factor (G-CSF) and TNF-alpha in patients with septic shock. Cytokine 2001; 13:51-54
34. Gross-Weege W, Weiss M, Schneider M, et al: Safety of a low-dosage Filgrastim (rh G-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process. Intensive Care Med 1997; 23:16-22
35. Kragsbjerg P, Holmberg H, Vikerfors T: Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand J Infect Dis 1996; 28:391-398
36. Stoltz DA, Bagby GJ, Nelson S: Use of granulocyte colony-stimulating factor in the treatment of acute infectious diseases. Curr Opin Hematol 1997; 4:207-212
37. Lee KY, Sub BG, Kim JW, et al: Varying expression levels of colony stimulating factor receptors in disease states and different leukocytes. Exp Mol Med 2000; 32:210-215
38. Pettila V, Takkunen O, Varpula T, et al: Safety of granulocyte colony-stimulating factor (illgrastim) in intubated patients in the intensive care unit: Interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med 2000; 28:3620-3625
39. Gruson D, Hilbert G, Vargas F, et al: Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients. Crit Care Med 2000; 28: 3155-3160
40. Tanaka H, Nishino M, Nakamori Y, et al: Granulocyte colony-stimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J Trauma 2001; 51: 1110-1116
41. Bedford Russell AR, Emmerson AJ, Wilkinson N, et al: A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed 2001; 84: F172-F176
42. Miura E, Procianoy RS, Bittar C, et al: A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to pre-term infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107: 30-35
43. Barth E, Fischer G, Schneider EM, et al: Peaks of endogenous g-csf serum concentrations are followed by an increase in respiratory burst activity of granulocytes in patients with septic shock. Cytokine 2002; 17: 275-284
44. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992; 327:28-35
45. Ishikawa K, Tanaka H, Nakamori Y, et al: Difference in the responses after administration of granulocyte colony-stimulating factor in septic patients with relative neutropenia. J Trauma 2000; 48:814-824; Discussion 824-825
46. Duignan JP, Collins PB, Johnson AH, et al: The association of impaired neutrophil chemotaxis with postoperative surgical sepsis. Br J Surg 1986; 73:238-240
47. Yodice PC, Astiz ME, Kurian BM, et al: Neutrophil rheologic changes in septic shock. Am J Respir Crit Care Med 1997; 155:38-42
48. Tavares-Murta BM, Zaparoli M, Ferreira RB, et al: Failure of neutrophil chemotactic function in septic patients. Crit Care Med 2002; 30:1056-1061
49. Edmonds M, Bates M, Doxford M, et al: New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev 2000; 16(Suppl 1):S51-S54
50. Segal BH, Holland SM: Primary phagocytic disorders of childhood. Pediatr Clin North Am 2000; 47:1311-1338
51. de Lalla F, Pellizzer G, Strazzabosco M, et al: Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45:1094-1098
52. Bernstein HM, Pollock BH, Calhoun DA, et al: Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: A meta-analysis. J Pediatr 2001; 138:917-920
53. Rolando N, Clapperton M, Wade J, et al: Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects. Eur J Gastroenterol Hepatol 2000; 12:1323-1328
54. Turgeon N, Hovingh GK, Fishman JA, et al: Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis 2000; 2:15-21
55. Nelson S: Novel nonantibiotic therapies for pneumonia: Cytokines and host defense. Chest 2001; 119:419S-425S
56. von Aulock S, Hartung T: Potential for immune reconstitution through G-CSF treatment of HIV patients. Arch Immunol Ther Exp (Warsz) 2002; 50:111-120
57. Stephens DP, Fisher DA, Currie B J: An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 2002; 32:143-148
58. Hartung T, von Aulock S, Wendel A: Growth factors G-CSF and GM-CSF: Clinical options. In: Multiple Organ Failure - Pathophysiology, Prevention and Therapy. Baue AE, Faist E, Fry DE (Eds). New York, Springer, 2000, pp 621-629
59. Hartung T, Gaviria JM, Garrido SM, et al: G-CSF and GM-CSF. In: Cytokine Therapeutics in Infectious Diseases. Holland SM (Ed). Philadelphia, Lippincott Williams & Wilkins, 2001, pp 185-219
60. Hubel K, Mansmann G, Schafer H, et al: Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. Cytokine 2000; 12:1797-1800
61. Faist E, Zedler S, et al: Perioperative rh G-CSF administration prevents monocytic deactivation and simultaneously attenuates inflammatory acute phase responses in patients undergoing major surgery. Abstract book. 21st Annual Meeting of the Surgical Infection Society, May 2001
62. Faist E, Schneider C, Hartung T, et al: Perioperative granulocyte-colony stimulating factor (G-CSF). Administration Prevents Immunodepression in Patients Undergoing Major Surgery. Abstract book. 121st Annual Meeting of the American Surgical Association, April 2001
63. Bernard GR, Vincent JL, Laterre PF, et al: For the Recombinant Human Activated Protein C World Wide in Severe Sepsis (PROWESS) Study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:69
64. Faist E, Markewitz A, Fuchs D, et al: Immunomodulatory therapy with thymopentin and indomethacin: Successful restoration of interleukin-2 synthesis in patients with major surgery. Ann Surg 1991; 214:264-274
65. Briegel J, Forst H, Haller M, et al: Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-732
66. Annane D: Effects of the combination of hydrocortisone (HC)-fluoro-cortisone (FC) on mortality in septic shock. Crit Care Med 2000; 28(Suppl):A63